Welcome to the Lilly Scientific Information Page for ASH 2025
American Society of Hematology
Orlando, Florida
Quicklinks
See how Lilly supports external requests for provision of study drug and/or financial support.
To receive the latest science and disease state education from Lilly Oncology, be sure to follow us via @LillyOncMed
To receive the latest science and innovation, please be sure to follow us on LinkedIn.
Disclosures
SATURDAY
- Disease State: Waldenström Macroglobulinemia
- Presented by: Chan Cheah
- Molecule(s): Pirtobrutinib
Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström Macroglobulinemia (WM): Up to 5 Years of Follow-Up from the Phase 1/2 BRUIN Study
Trial(s) Overview:
SATURDAY
- Disease State: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
- Presented by: William Wierda
- Molecule(s): Pirtobrutinib
Pirtobrutinib in Post-cBTKI CLL/SLL: Final Update from the Phase 1/2 BRUIN Study with More Than 5 Years Follow-Up
Trial(s) Overview:
SATURDAY
SATURDAY
- Disease State: Mantle-Cell Lymphoma
- Presented by: Yuqin Song
- Molecule(s): Pirtobrutinib
Real-World Characteristics, Treatment Patterns and Outcomes of Patients with Mantle Cell Lymphoma (MCL) After Receiving Covalent Bruton Tyrosine Kinase Inhibitors (cBTKi) in China
Trial(s) Overview:
Not Applicable
SUNDAY
- Disease State: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
- Presented by: Jennifer Woyach
- Molecule(s): Pirtobrutinib
Pirtobrutinib vs Ibrutinib in Treatment-Naïve and Relapsed/Refractory CLL/SLL: Results from the First Randomized Phase III Study Comparing a Non-Covalent and Covalent BTK Inhibitor
Trial(s) Overview:
SUNDAY
- Disease State: Mantle-Cell Lymphoma
- Presented by: Michael Wang
- Molecule(s): Pirtobrutinib
Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final Update from the Phase 1/2 BRUIN Study
Trial(s) Overview:
MONDAY
- Disease State: B-cell Malignancies
- Presented by: Krish Patel
- Molecule(s): BAFF-R CD3
BAF_FRontier-1: A First-in-Human Phase 1 Trial of LY4152199, a B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody, in Patients with Previously Treated B-cell Malignancies (Trial in Progress)
Trial(s) Overview:
MONDAY
- Disease State: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
- Presented by: Toby Eyre
- Molecule(s): Pirtobrutinib
Pirtobrutinib Outcomes in Second Line (2L) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) after First-Line (1L) cBTKi Therapy: A Pooled Analysis from the BRUIN LOXO-BTK-18001 and BRUIN CLL-321 Studies
Trial(s) Overview:
MONDAY
MONDAY
TUESDAY
- Disease State: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
- Presented by: Wojciech Jurczak
- Molecule(s): Pirtobrutinib
Pirtobrutinib vs Bendamustine Plus Rituximab (BendaR) in Patients With CLL/SLL: First Results from a Randomized Phase III Study Examining a Non-Covalent BTK Inhibitor in Untreated Patients.
Trial(s) Overview:
To receive the latest science and innovation from LillyMedical, be sure to follow us via our Twitter handle @LillyOncMed. See our community guidelines.
Contact Us
Call us
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)